Literature DB >> 3734315

Clinical digoxin toxicity in the aged in association with co-administered verapamil. A report of two cases and review of the literature.

M Gordon, L M Goldenberg.   

Abstract

Digoxin toxicity occurs more commonly in aged than younger individuals. Cardioactive drugs such as quinidine effect digoxin pharmacokinetics so as to increase the potential for digoxin toxicity. The calcium-channel antagonists have become extensively used for cardiac disorders and are often co-administered with digoxin. Despite documented calcium-channel antagonist interactions with digoxin, clinically significant digoxin toxicity associated with their concurrent use is apparently unusual. Two elderly patients receiving digoxin and verapamil simultaneously are presented to demonstrate the clinical importance and potential danger of the concomitant use of these drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734315     DOI: 10.1111/j.1532-5415.1986.tb04908.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  5 in total

1.  Prescribing drugs for the elderly: reaching therapeutic goals.

Authors:  H G Preiksaitis; M Gordon
Journal:  Can Fam Physician       Date:  1986-12       Impact factor: 3.275

2.  Interaction between Ca2+ antagonists and digitalis.

Authors:  J N Lessem
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  The interaction of the calcium antagonist RO 40-5967 with digoxin.

Authors:  M Siepmann; C Kleinbloesem; W Kirch
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

5.  Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.

Authors:  Kaitlyn V Ledwitch; Robert W Barnes; Arthur G Roberts
Journal:  Biosci Rep       Date:  2016-01-28       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.